Cytokine-Induced Memory-Like Natural Killer Cells
Ovarian Clear Cell Adenocarcinoma
Explore 32 assets in Ovarian Clear Cell Adenocarcinoma →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Dana-Farber Cancer Institute
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06321484CT.gov Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Clear Cell Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cytokine-Induced Memory-Like Natural Killer Cells (this asset) | Dana-Farber Cancer Institute | P1 | CC · 43 |
| Carboplatin | NRG Oncology | P3 | BBB |
| Olaparib | National Cancer Institute (NCI) | P3 | BB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Cediranib | National Cancer Institute (NCI) | P3 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P3 | BB |
| Pembrolizumab | Roswell Park Cancer Institute | P2 | B |
| Nogitecan | National Cancer Institute (NCI) | P2/3 | B |
+33 more in the Ovarian Clear Cell Adenocarcinoma cohort
Other indications for Cytokine-Induced Memory-Like Natural Killer Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Endometrioid Adenocarcinoma | — | P1 | CC · 43 |
| Ovarian Carcinoma | — | P1 | CC · 41 |
| Ovarian Cancer | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cytokine-Induced Memory-Like Natural Killer Cells in Ovarian Clear Cell Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cytokine-induced-memory-like-natural-killer-cells-ovarian-clear-cell-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →